Compare Braze Inc (BRZE) vs Oscar Health Inc (OSCR) Price & Performance

Braze (BRZE) trades at $26.60, up 5.85% with strong bullish momentum. The stock shows robust revenue growth, increasing from $238M in 2022 to $593M in 2025, though profitability remains negative with a -15.51% net margin. Technical indicators show bullish moving averages but overbought RSI levels. Recent news highlights Goldman Sachs initiation and strong Q1 2027 results with accelerating revenue growth and AI-driven customer engagement tools.

Outlook remains positive with 96% analyst buy ratings and $34.78 consensus target, representing 31% upside. Key risks include persistent losses despite revenue growth and competitive pressures in customer engagement software. The company's AI capabilities and fourth straight quarter of organic revenue acceleration provide growth catalysts, but investors should monitor profitability improvements.

OSCR trades at $31.60, up 3.47% today, showing strong momentum near recent highs. The stock exhibits a bullish technical outlook with positive moving average signals and support at $31. Recent Q1 2026 earnings beat expectations with $2.07 EPS versus $1.21 expected, though the company remains unprofitable with a -0.3% net margin. Revenue growth is robust, projected to increase from $11.70B in 2025 to $13.30B in 2026, while operating cash flow strengthens significantly.

The outlook is mixed: strong revenue growth and cash flow improvements support upside potential, but persistent losses and high P/B ratio of 5.63 pose risks. Analyst consensus is cautious with a $22.50 price target below current levels, though technical momentum suggests near-term strength. Key risks include execution on profitability goals and competitive pressures in the health insurance sector.